{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Simon C Langton Hewer, Alan R Smyth, Michaela Brown, Ashley P Jones, Helen Hickey, Dervla Kenna, Deborah Ashby, Alexander Thompson, Laura Sutton, Dannii Clayton, Barbara Arch, Łukasz Tanajewski, Vladislav Berdunov & Paula R Williamson.

Simon C Langton Hewer ^1,2,*,†, Alan R Smyth ^3,†, Michaela Brown ⁴, Ashley P Jones ⁴, Helen Hickey ⁴, Dervla Kenna ⁵, Deborah Ashby ⁶, Alexander Thompson ⁷, Laura Sutton ⁴, Dannii Clayton ⁴, Barbara Arch ⁴, Łukasz Tanajewski ⁸, Vladislav Berdunov ⁸, Paula R Williamson ⁴

¹ Department of Paediatric Respiratory Medicine, Bristol Royal Hospital for Children, ,
² University of Bristol, Bristol, UK
³ Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK
⁴ Liverpool Clinical Trials Centre, University of Liverpool, a member of the Liverpool Health Partners, Liverpool, UK
⁵ Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, UK
⁶ School of Public Health, Imperial College London, London, UK
⁷ Manchester Centre for Health Economics, The University of Manchester, Manchester, UK
⁸ Division of Pharmacy Practice and Policy, School of Pharmacy, University of Nottingham, Nottingham, UK
^* Corresponding author Email: simon.langtonhewer@bristol.ac.uk

^† Joint first author

Joint first author

Declared competing interests of authors: Alan R Smyth reports grants from Vertex Pharmaceuticals, Inc. (Boston, MA, USA), personal fees from Vertex Pharmaceuticals, Inc., non-financial support from Teva Pharmaceuticals (Petah Tikva, Israel) and non-financial support from Novartis International AG (Basel, Switzerland) outside the submitted work. In addition, Alan R Smyth has a patent for alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof issued and was a member of the Health Technology Assessment (HTA) Clinical Evaluation and Trials Committee (from 1 April 2011 to 1 April 2016). Deborah Ashby has been a member of various National Institute for Health Research (NIHR) Committees from 2008 to 2018 [HTA Commissioning Sub-Board (Expression of Interest) 1 April 2016 to 31 March 2017; HTA Funding Teleconference Members 31 May 2016 to 1 October 2016; NIHR Clinical Trials Unit Standing Advisory Committee 1 May 2008 to 1 May 2014; HTA Board Recruitment 1 January 2016 to 31 December 2018; HTA Remit and Competitiveness Group 1 May 2018 to 30 November 2018; HTA Funding Committee Policy Group (formerly Commissioning Strategy Group) 1 November 2015 to 30 November 2018, Imperial College London; and HTA Commissioning Committee, 1 November 2015 to 31 December 2018, all while at Imperial College London]. In additon, Deborah Ashby is supported by NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. Paula R Williamson was Director of Liverpool Clinical Trials Centre (April 2005–December 2018; formerly Medicines for Children Clinical Trials Unit), which received funding from NIHR (end date 31 August 2021), and reports grants from the University of Liverpool, during the conduct of the study. We would like to thank the European Cystic Fibrosis Society Clinical Trial Network for its help and financial support in setting up the trial in Italy.